Making Sense of Immunotherapy in Lung Cancer: What the Pulmonologist Needs to Know?
- 77 Downloads
Purpose of Review
The landscape of lung cancer therapy has completely shifted in the last decade. From the surge of targeted therapy to the resurrection of immunotherapy, the need for adequate lung tissue specimen is critical to evaluate tumor specimens for predictive biomarkers for both types of therapies, hence, the importance of obtaining several samples via endoscopic bronchial ultrasound performed by pulmonologists or thoracic surgeons. Moreover, these novel therapies have also been associated with respiratory side effects which will require prompt evaluation and aggressive management by pulmonologists, oncologists, and intensive care unit personnel.
Pneumonitis is commonly coined to refer to interstitial lung disease. It is a side effect from checkpoint inhibitors, a type of immunotherapy, which has proved overall survival advantage in lung cancer patients in different clinical settings: first- and second-line therapy for metastatic non-small cell lung cancers as well as for locally advanced disease after being treated with concurrent chemoradiation. Thus, the number of patients who will be exposed to these agents is considerable, and we should expect to see an increased management of this autoimmune phenomenon as well as others.
The mechanism of checkpoint inhibitor-induced pneumonitis is not well understood yet, but its management is like that of other autoimmune complications that affect the lung parenchyma. Prompt recognition is critical to avoid a fatal outcome.
KeywordsCheckpoint inhibitor Immunotherapy Interstitial lung disease Lung cancer Pneumonitis Pulmonary toxicity
Compliance with Ethical Standards
Conflict of Interest
Edgardo Santos reports speaker bureau fees from Genentech, Merck, Astrazeneca, Takeda, Novartis, Pfizer, Boehringer-Ingelheim, Celgene, and Lilly. Luis Raez reports research grants from Merck, BMS, Genentech, Astrazeneca, and Syndax. Christian Rolfo reports speaker bureau fees from Merck Serono (MSD). Moises Harari and Lilibeth Castillero declare no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance ••Of major importance
- 1.American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society.Google Scholar
- 4.• Brahmer J, Reckamp KL, Bass P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123–35. Landmark study establishing nivolumab (first checkpoint inhibitor) as therapy in lung cancer. CrossRefPubMedPubMedCentralGoogle Scholar
- 9.•• Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730. Large meta-analysis including 46 studies where investigators described irAEs associated with the use of PD-1 inhibitors; occurrence of these AEs is organ-specific, related to drug and tumor type. CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.CrossRefPubMedGoogle Scholar
- 11.Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.CrossRefPubMedGoogle Scholar
- 12.• Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. Landmark study establishing pembrolizumab as the only checkpoint inhibitor used as monotherapy in first line metastatic NSCLC. CrossRefPubMedGoogle Scholar
- 13.• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–29. Unmet need in oncology was reached after this study; finally, a therapy improved PFS after “definitive” concurrent chemoradiation for stage III NSCLC. CrossRefPubMedGoogle Scholar
- 14.•• Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 2017;50(2):1–13. https://doi.org/10.1183/13993003.00050-2017. Description of main features of IO-induced ILD with a focus on clinical presentation, radiological patterns, and therapeutic strategies which can help clinicians to recognize this phenomenon promptly.
- 19.Adler S, Huscher D, Siegert E, Allanore Y, Czirjak L, DelGaldo F, et al. Systemic sclerosis associated interstitial lung disease—individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018;20(1):17.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018; https://doi.org/10.1001/jamaoncol.2017.4526.